RE:RE:RE:Investors should know RHT’s unique advantage ilaurence: Just looking at one of the companies you mentioned - Teledoc - I can see that, after many years of operating, they lost US$84.60 per share in the last twelve months, probably because their business model is different from Reliq's. To be fair, most of that loss was related to a US$13 billion impairment charge, so they should get some credit for that, I suppose. And, their revenue was up 18% in their trailing twelve months, so that's something too.
Reliq, on the other hand, with modest revenue of only $12.4M, had 170% trailing twelve month revenue growth and almost broke even in their last quarter. I know, you probably want to give them credit for their one time forex loss, which, if excluded, would've resulted in a about a $140k profit, but let's be conservative and not get too far ahead of ourselves.
To be blunt, if Reliq can get past the adherence and collections hurdles, they should be able to shoot the lights out. The company says they're making progress, but we need confirming data before uncorking the champagne. Working through the bugs has been difficult here and progress sometimes has been slow, but the rewards could be maginificent.